A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan

Name: A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan
Creator: Vivli
Published: 2025-03-04 16:14:36
License: 暂无描述

DataCite Commons2025-03-04 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00003231/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.

提供机构：

Vivli

创建时间：

2018-10-27